24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring

被引:52
作者
Fogari, R
Ambrosoli, S
Corradi, L
Esposti, ED
Mos, L
Nami, R
Nicrosini, F
Pessina, AC
Salvetti, A
Vaccarella, A
Zanchetti, A
Martin, A
Reeves, RA
机构
[1] UNIV PAVIA,DEPT INTERNAL MED,I-27100 PAVIA,ITALY
[2] OSPED CIVILE,FIDENZA,ITALY
[3] OSPED GEN,BRONI,ITALY
[4] OSPED S MARIA CROCI,RAVENNA,ITALY
[5] STABILIMENTO OSPED,S DANIELE DEL FRIULI,ITALY
[6] UNIV SIENA,POLICLIN,I-53100 SIENA,ITALY
[7] OSPED CIVILE,VOGHERA,ITALY
[8] UNIV PADUA,POLICLIN,PADUA,ITALY
[9] UNIV PISA,POLICLIN S CHIARA,PISA,ITALY
[10] INRCA,CASATENOVO,ITALY
[11] UNIV MILAN,OSPED MAGGIORE,IRCCS,CTR AUXOL ITALIANO,MILAN,ITALY
[12] BRISTOL MYERS SQUIBB PHARMACEUT RES INST,PRINCETON,NJ 08543
[13] BRISTOL MYERS SQUIBB INT CORP,WATERLOO,BELGIUM
关键词
ambulatory blood pressure monitoring; irbesartan; hypertension; angiotensin II receptor antagonist; placebo-controlled trial;
D O I
10.1097/00004872-199715120-00020
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objectives To compare 24 h ambulatory blood pressure and trough office blood pressure lowerings after 8 weeks of therapy with 75 mg irbesartan once a day, 150 mg irbesartan once a day, and 75 mg irbesartan twice a day versus placebo; and to assess safety and tolerability of irbesartan therapy. Design Multicenter, double-blind, randomized, placebo-controlled trial. Setting Sixteen centers in Italy. Patients Caucasian patients (n = 215) aged greater than or equal to 18 years with seated diastolic blood pressure 95-110 mmHg and ambulatory diastolic blood pressure (ADBP) greater than or equal to 85 mmHg. Primary outcome Mean 24 h ADBP after 8 weeks of irbesartan therapy. Results Mean changes (value before treatment minus value after treatment) in ADBP for placebo, 75 mg irbesartan once a day, 150 mg irbesartan once a day, and 75 mg irbesartan twice a day were -0.2, -5.4, -7.2, and -7.2 mmHg, respectively; respective changes in ambulatory systolic blood pressure were +1.6, -8.3, -10.5, -9.7 and mmHg. All irbesartan regimens reduced -9.7 trough office seated diastolic blood pressure and seated systolic blood pressure after 2 and 8 weeks of treatment (all P < 0.01, versus placebo except for seated systolic blood pressure in patients in the 75 mg irbesartan once a day group). Trough : peak ratios were greater than or equal to 55% with 150 mg irbesartan once a day. Percentages of patients whose blood pressures were normalized with 150 mg irbesartan once a day (45%) and 75 mg irbesartan twice a day (47%) were greater than those with placebo (14%, P < 0.01) and with 75 mg irbesartan once a day (19%, NS, versus placebo). Adverse events with irbesartan were similar to those with placebo. Conclusions All irbesartan regimens significantly reduced mean 24 h ADBP and ambulatory systolic blood pressure, and were well tolerated. Administration of 150 mg irbesartan once a day provided significant reduction of blood pressure for 24 h, equivalent to that obtained with the same daily dose divided into two separate administrations.
引用
收藏
页码:1511 / 1518
页数:8
相关论文
共 19 条
[1]  
CAZAUBON C, 1993, J PHARMACOL EXP THER, V265, P826
[2]  
Hagmann M., 1994, American Journal of Hypertension, V7, p13A
[3]  
*JOINT NAT COMM DE, 1993, ARCH INTERN MED, V153, P154
[4]  
LIPICKY RJ, 1994, J HYPERTENS, V12, pS17
[5]  
Mancia G, 1995, J HYPERTENS, V13, P1377
[6]   LIMITED REPRODUCIBILITY OF HOURLY BLOOD-PRESSURE VALUES OBTAINED BY AMBULATORY BLOOD-PRESSURE MONITORING - IMPLICATIONS FOR STUDIES ON ANTIHYPERTENSIVE DRUGS [J].
MANCIA, G ;
OMBONI, S ;
PARATI, G ;
TRAZZI, S ;
MUTTI, E .
JOURNAL OF HYPERTENSION, 1992, 10 (12) :1531-1535
[7]   LACK OF PLACEBO-EFFECT ON AMBULATORY BLOOD-PRESSURE [J].
MANCIA, G ;
OMBONI, S ;
PARATI, G ;
RAVOGLI, A ;
VILLANI, A ;
ZANCHETTI, A .
AMERICAN JOURNAL OF HYPERTENSION, 1995, 8 (03) :311-315
[8]  
MARINO MR, 1996, J HYPERTENS, V14, pS348
[9]  
MARTINEZ F, 1994, J AM SOC NEPHROL, V5, P607
[10]   Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men [J].
McIntyre, M ;
MacFadyen, RJ ;
Meredith, PA ;
Brouard, R ;
Reid, JL .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (01) :101-106